Sign In
HHS Logo
U.S. Department of Health & Human Services
Search Icon
Menu Icon

Module 3: Oral Antiviral Administration


Federal Response to COVID-19: Therapeutics Clinical Implementation Guide (Outpatient Administration Guide for Healthcare Providers)


Patient Flow for Antiviral Oral Therapies

(When product not available onsite)

comments icon Assessment and Prescribing

  • Confirm diagnosis of COVID-19 infection
  • Discuss treatment with patient
    • Ensure patient meets treatment requirements and understands risks
  • Prescribe therapy for patient & provide the medication fact sheet (for product under EUA)

stethoscope icon Visit Discharge

  • Prescription provided to the patient
    • Ensure patient understands medication therapy being provided
    • Ensure medication therapy being dispensed complies with federal/state dispensing laws
  • Discuss treatment with patient
    • Ensure patient meets treatment requirements and understands risks
  • Prescribe therapy for patient & provide the medication fact sheet (for product under EUA)
    • Document required patient assessment in medical record
    • Provide patient education on medication therapy being prescribed
  • Determine locations medication is available in local area.

Return visit icon Post-visit

  • Pharmacist receives or prescribes patient prescription
    • Pharmacy should prioritize the prescription fill and ensure timely turnaround to support same day start for therapy
    • Pharmacist verifies prescription is appropriate for patient.  Any concerns are clarified with prescribing provider
  • Pharmacy staff dispenses product to the patient 
    • Patient is counseled on medication therapy and reminded to start immediately
  • Patient to begin prescribed therapy immediately and continue x 5 days
  • Patient to report any adverse effect to FDA MedWatch
    • Patients that present for hospital visit may continue their prescribed antiviral during hospitalization (at discretion of provider)


Test to Treat: About the Program

  • Overall goal of Test to Treat program is to increase access to COVID-19 oral therapeutics, particularly for individuals who don’t have ready access to a health care provider
    Screenshot of the Test to Treat flyer
  • COVID-19 treatments delivered as part of Test to Treat Program (Paxlovid and Lagevrio) must be taken within 5 days of initial COVID-19 symptoms.
    • Helps close gap between positive COVID-19 test and receiving treatment for those eligible
  • Builds upon existing distribution of oral antivirals we are already making available at no cost to thousands of locations nationwide 
  • An individual’s healthcare providers remain the first option for care; Test to Treat sites are one additional access point.


Test to Treat Site Locator

  • Identifies all Test to Treat program sites and all sites to fill an existing prescription
    • Visibility of telehealth and home delivery options on locator Screenshot of the Test to Treat locator website
  • Call center also available: 1-800-232-0233 (TTY 1-888-720-7489) to get help in English, Spanish, and more than 150 other languages—8 AM to 8 PM ET Monday through Friday, 8 AM to 5 PM ET Saturday and Sunday
  • Disability Information and Access Line (DIAL) also available to specifically help those with disabilities access services. 1-888-677-1199, Monday to Friday from 8 AM to 9 PM ET or email DIAL@usaginganddisability.org.


To use the tool to find a location, visit COVID-19 Test to Treat Site Locator









​
CIG Right-Nav

Federal Response to COVID-19: Therapeutics CIG